Teicoplanin is not approved for marketing in the United States by the U.S. Food and Drug Administration, but is available in other countries. Limited data indicate that teicoplanin is poorly excreted into breastmilk. Because teicoplanin is not orally absorbed it is unlikely to adversely affect the breastfed infant. One infant was safely breastfed during maternal therapy with teicoplanin and ceftriaxone. Until more information becomes available, monitor the breastfed infant for gastrointestinal disturbances such as diarrhea, particularly in newborn and preterm infants.
替考拉宁尚未获得美国食品药品监督管理局批准在美国上市，但在其他国家有售。有限的数据表明，替考拉宁经母乳排泄的量很少。由于替考拉宁不会经口服吸收，因此不太可能对母乳喂养的婴儿产生不利影响。有一名婴儿在其母亲接受替考拉宁和头孢曲松治疗期间安全地接受了母乳喂养。在获得更多信息之前，应对母乳喂养的婴儿进行监测，观察是否出现胃肠道紊乱症状，如腹泻，尤其是在新生儿和早产儿中。
